Introduction: Currently, severe acute respiratory syndrome coronavirus (SARS-CoV-2) infection is a major public health problem worldwide. Although most patients present a mild infection, effective strategies are required for patients who develop the severe disease. Anti-inflammatory treatment with JAK inhibitors has been considered in SARS-CoV-2. Methods: In this study, we presented our experience in a group of severe SARS-CoV-2 Chilean patients. This prospective study was performed on consecutive patients presenting severe respiratory failure owing to COVID-19 or high-risk clinical condition associated with SARS-CoV-2, and who were treated with ruxolitinib for management of associated inflammation. Overall, 18 patients presenting SARS-CoV-2 viral-induced hyperinflammation were treated with ruxolitinib, with 16 patients previously treated with steroids, 4 with tocilizumab, and 3 with both treatments. Results: Ten patients evolved with favorable response, including 7 patients admitted with severe respiratory failure (PaFi less than 200 mm Hg in high-flow nasal cannula), presenting complete regression of hyperinflammation, regression of the lung lesions, and subsequent discharge. In the remaining 8 patients, 25% showed reduced inflammation, but early discharge was not achieved owing to the slow evolution of respiratory failure. Unfortunately, 3 patients demonstrated a severe respiratory failure. The early initiation of ruxolitinib was found to be associated with better clinical evolution (p < 0.005). Conclusion: In this study, ruxolitinib resolved hyperinflammatory state in 55% of the patients, regardless of the previous steroid or tocilizumab therapy. Unfortunately, few patients demonstrated severe evolution despite ruxolitinib therapy. Notably, the treatment starting time appears to play an important role in achieving good outcomes. Further validation in randomized controlled trials is crucial.

1.
Schett
G
,
Sticherling
M
,
Neurath
MF
.
COVID-19: risk for cytokine targeting in chronic inflammatory diseases?
Nat Rev Immunol
.
2020
;
20
(
5
):
271
2
. .
2.
Chen
LYC
,
Hoiland
RL
,
Stukas
S
,
Wellington
CL
,
Sekhon
MS
.
Confronting the controversy: interleukin-6 and the COVID-19 cytokine storm syndrome
.
Eur Respir J
.
2020 Oct 1
;
56
(
4
):
2003006
. .
3.
Zeiser
R
,
von Bubnoff
N
,
Butler
J
,
Mohty
M
,
Niederwieser
D
,
Or
R
,
Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease
.
N Engl J Med
.
2020
;
382
(
19
):
1800
10
. .
4.
Birndt
S
,
Schenk
T
,
Heinevetter
B
,
Brunkhorst
FM
,
Maschmeyer
G
,
Rothmann
F
,
Hemophagocytic lymphohistiocytosis in adults: collaborative analysis of 137 cases of a nationwide German registry
.
J Cancer Res Clin Oncol
.
2020
;
146
(
4
):
1065
77
. .
5.
Hermans
MAW
,
Schrijver
B
,
van Holten-Neelen
CCPA
,
Gerth van Wijk
R
,
van Hagen
PM
,
van Daele
PLA
,
The JAK1/JAK2-inhibitor ruxolitinib inhibits mast cell degranulation and cytokine release
.
Clin Exp Allergy
.
2018
;
48
(
11
):
1412
20
. .
6.
Khadka
RH
,
Sakemura
R
,
Kenderian
SS
,
Johnson
AJ
.
Management of cytokine release syndrome: an update on emerging antigen-specific T cell engaging immunotherapies
.
Immunotherapy
.
2019
;
11
(
10
):
851
7
. .
8.
Goker Bagca
B
,
Biray Avci
C
.
The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19
.
Cytokine Growth Factor Rev
.
2020
;
54
(
20
):
51
62
. .
9.
Pairo-Castineira
E
,
Clohisey
S
,
Klaric
L
,
Bretherick
AD
,
Rawlik
K
,
Pasko
D
,
Genetic mechanisms of critical illness in Covid-19
.
Nature
.
2020 Mar
;
591
(
7848
):
92
8
.
10.
Tefferi
A
,
Pardanani
A
.
Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis
.
Mayo Clin Proc
.
2011 Dec
;
86
(
12
):
1188
91
. .
11.
Galimberti
S
,
Baldini
C
,
Baratè
C
,
Ricci
F
,
Balducci
S
,
Grassi
S
,
The CoV-2 outbreak: how hematologists could help to fight Covid-19
.
Pharmacol Res
.
2020
;
157
:
104866
. .
12.
Elli
EM
,
Baratè
C
,
Mendicino
F
,
Palandri
F
,
Palumbo
GA
.
Mechanisms underlying the anti-inflammatory and immunosuppressive activity of ruxolitinib
.
Front Oncol
.
2019
;
9
:
1186
. .
13.
Cao
Y
,
Wei
J
,
Zou
L
,
Jiang
T
,
Wang
G
,
Chen
L
,
Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter, single-blind, randomized controlled trial
.
J Allergy Clin Immunol
.
2020
;
S0091–6749
(
20
):
30738
7
.
14.
La Rosée
F
,
Bremer
HC
,
Gehrke
I
,
Kehr
A
,
Hochhaus
A
,
Brindt
S
,
The janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation
.
Leukemia
.
2020
:
1
11
.
15.
Rojas
P
,
Sarmiento
M
.
JAK/STAT pathway inhibition may be a promising therapy for COVID-19-related hyperinflammation in hematologic patients
.
Acta Haematol
.
2020 Jul 29
:
1
5
.
16.
Saraceni
F
,
Scortechini
I
,
Mancini
G
,
Mariani
M
,
Federici
I
,
Gaetani
M
,
Severe COVID-19 in a patient with chronic graft-versus-host disease after hematopoietic stem cell transplant successfully treated with ruxolitinib
.
Transpl Infect Dis
.
2020 Jul 6
:
e13401
. .
17.
Capochiani
E
,
Frediani
B
,
Iervasi
G
,
Paolicchi
A
,
Sani
S
,
Roncucci
P
,
Ruxolitinib rapidly reduces acute respiratory distress syndrome in COVID-19 disease. Analysis of data collection from RESPIRE protocol
.
Front Med
.
2020
;
7
:
466
. .
18.
RECOVERY Collaborative Group
;
Horby
P
,
Mafham
M
,
Linsell
L
,
Bell
JL
,
Staplin
N
,
Effect of dexamethasone in hospitalized patients with COVID-19–preliminary report
.
N Engl J Med
.
2020 Nov 19
;
383
(
21
):
2030
40
.
19.
Spagnolo
P
,
Balestro
E
,
Aliberti
S
,
Cocconcelli
E
,
Biondini
D
,
Casa
GD
,
Pulmonary fibrosis secondary to COVID-19: a call to arms?
Lancet Respir Med
.
2020 May 15
;
8
(
20
):
750
2
. .
20.
Ellinghaus
D
,
Degenhardt
F
,
Bujanda
L
,
Buti
M
,
Albillos
A
,
Invernizzi
P
,
Severe Covid-19 GWAS group. Genomewide association study of severe Covid-19 with respiratory failure
.
N Engl J Med
.
2020 Jun 17
;
383
:
1522
34
.
21.
Van der Made
CI
,
Simons
A
,
Schuurs-Hoeijmakers
J
,
van den Heuvel
G
,
Mantere
T
,
Kersten
S
,
Presence of genetic variants among young men with severe COVID-19
.
JAMA
.
2020
:
e2013719
. .
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.